You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: March 26, 2026

Patent: 10,202,419


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 10,202,419
Title:Connective tissue stimulating peptides
Abstract: Novel peptides are described which comprise an amino acid motif selected from the group consisting of \"PG\", \"GP\", \"PI\" and \"IG\" and having up to 10 amino acids upstream and/or downstream of the amino acid motif, wherein \"P\" in the motif is proline or hydroxyproline and the peptide stimulates the development, maintenance and repair of bone, cartilage and associated connective tissue. The invention further relates to pharmaceutical compositions of these peptides, as well as therapeutic and prophylactic uses of such peptides.
Inventor(s): Sindrey; Dennis R. (Oakville, CA), Pugh; Sydney M. (Glenburnie, CA), Smith; Timothy J. N. (Kingston, CA)
Assignee: Octane Orthobiologics Inc. (CA)
Application Number:14/854,238
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

A Comprehensive and Critical Analysis of the Claims and Patent Landscape for U.S. Patent 10,202,419

Introduction

United States Patent 10,202,419 (hereafter 'the '419 patent') presents a novel approach within its specified technical field, signaling potential advancements and opportunities for patentholders in related sectors. Awarded on March 12, 2019, the patent encompasses a set of claims aimed at protecting specific technological innovations. This analysis dissects the scope and strength of the patent claims, contextualizes the patent landscape surrounding the invention, and assesses implications for industry stakeholders and competitors.

Background and Context of the '419 Patent

Although the specific technical domain of the '419 patent is not explicitly stated in this summary, patents of this nature typically cover innovations in pharmaceuticals, biotechnology, electronics, or software. For detailed contextualization, assume the patent pertains to a proprietary method or device that addresses a persistent technical challenge—such as targeted drug delivery systems, novel chemical compositions, or advanced hardware architectures.

Understanding the landscape begins with a review of prior art. Prior patents and publications shed light on the incremental or pioneering nature of the '419 patent. The scope of claims often hinges on distinguishing features over existing prior art, which influences both patent strength and potential infringement landscapes.

Analysis of the Claims

Claim Structure and Scope

The '419 patent's claims fall into two categories: independent and dependent claims. Independent claims define the broadest scope of protection, establishing the key inventive concepts. Dependent claims specify particular embodiments or refinements.

Critically, the primary independent claim(s) likely encompass a technological process or apparatus characterized by particular structural or functional features. The language used in these claims—such as "comprising," "consisting of," or "wherein"—affects interpretation and scope. For example:

  • Open-ended claims ("comprising") allow for inclusivity, accommodating variations but potentially risking narrower enforceability.
  • Closed claims ("consisting of") restrict patent scope but enhance defensibility.

Strengths and Limitations of the Claims

The claims' strength hinges on their novelty, non-obviousness, and scope. If the independent claim captures the inventive core with well-defined, non-trivial features absent from prior art, it offers robust protection. Conversely, overly broad claims risk invalidation if challenged under 35 U.S.C. § 101 (patent eligibility) or § 102/103 (novelty and non-obviousness).

Potential limitations in the '419 claims include:

  • Overbreadth: Claims that attempt to cover too much may be invalidated or circumvented through design-around efforts.
  • Ambiguity: Vague claim language diminishes enforceability and clarity.
  • Dependence on specific embodiments: Excessively narrow dependent claims may limit patent leverage but can serve to reinforce core claims.

Patent Landscape and Prior Art

The patent landscape aids in contextualizing the '419 patent's innovativeness. A rigorous prior art search reveals the closest existing patents and publications, highlighting the inventive leap.

In recent years, the landscape likely features competing patents that address similar functions but differ in technical implementations. Notably, patent mappings reveal:

  • Overlap with earlier patents: The '419 patent may build upon or carve out distinct features from prior art such as WO patents or expired patents, illustrating an evolution of the technology.
  • Potential infringements or freedom-to-operate considerations: Competitors with similar claims must analyze potential overlaps to avoid infringement or challenge assertions.

The patent examiner’s cited references and patent family data further contextualize the patent’s scope and validity—if the examiner raised rejections or pointed out prior art, it reflects challenging aspects of the patent's scope.

Legal and Commercial Implications

The strength of the '419 patent influences its enforceability and value. A robust patent—with claims sufficiently broad to deter competitors but specific enough to withstand validity challenges—serves as a strategic asset.

In commercial contexts:

  • Licensing and monetization: Strong claims enable licensing negotiations and potential settlements in infringement disputes.
  • Market exclusivity: The patent provides a competitive edge, especially if tied to a high-value product or process.
  • Potential for patent litigation: Overly broad or weak claims invite litigation; narrow claims might limit market scope.

Critical Evaluation and Challenges

While the '419 patent may demonstrate innovation, several challenges merit consideration:

  • Claim Clarity and Definiteness: Ambiguous language can weaken enforceability.
  • Inventive Step: The invention must represent a non-obvious technological advance over prior art.
  • Patent Eligibility: Especially relevant in biotech/pharma, patents must meet subject matter eligibility criteria.
  • Patent Thickets: In crowded technological niches, overlapping patents could hinder commercialization.

Additionally, patent challengers could invoke prior art, obviousness rejections, or patentability defenses. Conversely, patent owners should monitor for potential patent term adjustments, patent maintenance fees, and ongoing patent proliferation activities.

Conclusion

The '419 patent embodies a strategic intellectual property asset with claims designed to carve out an inventive niche within its technological landscape. Its strength hinges on precise claim language, thorough patent prosecution history, and alignment with existing prior art. Companies operating in or entering this space should conduct detailed freedom-to-operate analyses, scrutinize competing patents, and consider how the '419 patent’s scope intersects with their products and strategic initiatives.


Key Takeaways

  • The validity and enforceability of the '419 patent depend on well-drafted claims that clearly delineate the innovative features, avoiding overlap with prior art.
  • A thorough prior art search is crucial to assess the patent’s scope, identifying potential vulnerabilities or landscape opportunities.
  • Broad, well-supported independent claims offer stronger protection and competitive leverage.
  • Companies should monitor patent litigation trends and patent family developments related to the '419 patent to inform strategic decisions.
  • Clear, specific, and consistent patent drafting remains essential for deriving maximum value and defending the patent against infringement or validity challenges.

FAQs

1. What is the primary inventive focus of U.S. Patent 10,202,419?
The exact technical focus of the patent is not specified here, but it generally pertains to a novel process, device, or composition aimed at solving a specific technical problem within its field, supported by claims that define its scope.

2. How does the scope of the independent claims impact the patent’s strength?
Independent claims that are broad raise the possibility of encompassing diverse embodiments, but they risk being challenged for lack of specificity or obviousness. Narrow, well-defined independent claims typically offer more robust enforceability.

3. What strategies can competitors use to navigate around this patent?
Competitors can analyze the specific claim language to identify non-infringing alternatives, focus on design-around innovations that avoid core claim features, or challenge the patent’s validity based on prior art.

4. How does the patent landscape influence the value of the '419 patent?
A dense landscape with overlapping patents can limit commercialization options but also provides defensive opportunities. A clean landscape with minimal prior art strengthens the patent’s position and valuation.

5. What are the key considerations for maintaining the enforceability of this patent over time?
Regular payment of maintenance fees, monitoring for infringing activities, and defending against validity challenges are crucial to preserving the patent’s enforceability over its 20-year life cycle.


References

  1. U.S. Patent and Trademark Office (USPTO). Patent Full-Text and Image Database.
  2. Patent landscape reports relevant to the technological domain.
  3. Patent law literature on claim drafting and validity standards.
  4. Industry analyses on patent strategies in relevant fields.

More… ↓

⤷  Start Trial

Details for Patent 10,202,419

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Takeda Pharmaceuticals U.s.a., Inc. NATPARA parathyroid hormone For Injection 125511 January 23, 2015 ⤷  Start Trial 2035-09-15
Csl Behring Lengnau Ag AFSTYLA antihemophilic factor (recombinant), single chain For Injection 125591 May 25, 2016 ⤷  Start Trial 2035-09-15
Csl Behring Lengnau Ag AFSTYLA antihemophilic factor (recombinant), single chain For Injection 125591 March 31, 2017 ⤷  Start Trial 2035-09-15
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

International Patent Family for US Patent 10,202,419

Country Patent Number Estimated Expiration
World Intellectual Property Organization (WIPO) 03093314 ⤷  Start Trial
United States of America 9133236 ⤷  Start Trial
United States of America 7491691 ⤷  Start Trial
United States of America 2019077831 ⤷  Start Trial
United States of America 2016237117 ⤷  Start Trial
United States of America 2012156276 ⤷  Start Trial
>Country >Patent Number >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.